Evidence map›Paper›PMID 30052661›Full record

ArticlePloS one2018

Effect of sodium 4-phenylbutyrate on Clenbuterol-mediated muscle growth.

David M Brown, Sarah Jones, Zoe C T R Daniel, Madelaine C Brearley, Jo E Lewis, Francis J P Ebling, Tim Parr, John M Brameld

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Response of the porcineBiochemistry and biophysics reports · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David M BrownSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
Sarah JonesSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
Zoe C T R DanielSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
Madelaine C BrearleySchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
Jo E LewisSchool of Life Sciences, University of Nottingham, Medical School, Nottingham, United Kingdom.
Francis J P EblingSchool of Life Sciences, University of Nottingham, Medical School, Nottingham, United Kingdom.
Tim ParrSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.
John M BrameldSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.ORCID 0000-0003-4942-080X
University of Nottingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/MM001385/1
6 · The paper itself

Abstract

Previously, we highlighted induction of an integrated stress response (ISR) gene program in skeletal muscle of pigs treated with a beta-adrenergic agonist. Hence we tested the hypothesis that the ER-stress inhibitor, sodium 4-phenylbutyrate (PBA), would inhibit Clenbuterol-mediated muscle growth and reduce expression of genes that are known indicators of an ISR in mice. Clenbuterol (1mg/kg/day) administered to C57BL6/J mice for 21 days increased body weight (p<0.001), muscle weights (p<0.01), and muscle fibre diameters (p<0.05). Co-administration of PBA (100mg/kg/day) did not alter the Clenbuterol-mediated phenotype, nor did PBA alone have any effects compared to that of the vehicle treated mice. Clenbuterol increased skeletal muscle mRNA expression of phosphoserine amino transferase 1 (PSAT1, p<0.001) and cyclophillin A (p<0.01) at day 3, but not day 7. Clenbuterol decreased mRNA expression of activating transcription factor (ATF) 4 and ATF5 at day 3 (p<0.05) and day 7 (p<0.01), X-box binding protein 1 (XBP1) variant 2 mRNA at day 3 only (p<0.01) and DNA damage inducible transcript 3 (DDIT3/CHOP) mRNA at day 7 only (p<0.05). Co-administration of PBA had no effect on Clenbuterol-induced changes in skeletal muscle gene expression. In contrast, treatment of C2C12 myotubes with 5mM PBA (8hr) attenuated the thapsigargin-induced ISR gene program. Prolonged (24-48hr) treatment with PBA caused atrophy (p<0.01), reduced neoprotein synthesis (p<0.0001) and decreased expression of myogenin and fast myosin heavy chain genes (p<0.01), indicating an inhibition of myogenic differentiation. In summary, Clenbuterol did not induce an ISR gene program in mouse muscle. On the contrary, it reduced expression of a number of ISR genes, but it increased expression of PSAT1 mRNA. Co-administration of PBA had no effect on Clenbuterol-mediated muscle growth or gene expression in mice, whereas PBA did inhibit thapsigargin-induced ISR gene expression in cultured C2C12 cells and appeared to inhibit myogenic differentiation, independent of altering ISR gene expression.

Indexed as

AnimalsBody WeightClenbuterolGene Expression RegulationMaleMiceMuscle ProteinsMuscle, SkeletalPhenylbutyratesRNA, MessengerSwine4-phenylbutyric acidClenbuterolMuscle ProteinsPhenylbutyratesRNA, Messenger

Identifiers

PMID30052661
PMCPMC6063449
OpenAlexW2883513997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.